文献速递胸部肿瘤

纳武利尤单抗治疗复发性恶性胸膜间皮瘤

Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma.
PubMed 文献 · J Thorac Oncol · 2018-06-14

这项单中心试验纳入34例复发性恶性胸膜间皮瘤患者,每2周静脉给予纳武利尤单抗3 mg/kg。12周疾病控制率为47%,8例(24%)达部分缓解;任何级别治疗相关不良事件发生率为76%,3-4级为26%。PD-L1在27%的样本中表达,但与疗效无关。

要点

  • 纳武利尤单抗在经治复发性胸膜间皮瘤中12周疾病控制率达47%
  • 任何级别治疗相关不良事件76%,3-4级26%,需警惕肺炎
  • PD-L1表达与疗效无关,不能作为预测标志物

核心结论

  • 单药纳武利尤单抗在经治恶性胸膜间皮瘤患者中具有有意义的临床疗效和可控的安全性。
  • PD-L1表达不能预测该人群的疗效。

研究设计与样本

  • 单中心试验,纳入34例复发性恶性胸膜间皮瘤患者。
  • 纳武利尤单抗3 mg/kg静脉给药,每2周一次。
  • 主要终点为12周疾病控制率;治疗前和治疗中活检用于分析疗效生物标志物。

主要发现

  • 34例患者中8例(24%)在12周达部分缓解,另8例疾病稳定,12周疾病控制率为47%。
  • 1例在18周达部分缓解;4例疾病稳定患者肿瘤稳定超过6个月。
  • 任何级别治疗相关不良事件发生于26例(76%),最常见为乏力(29%)和瘙痒(15%)。
  • 3级和4级治疗相关不良事件发生于9例(26%),主要为肺炎、胃肠道疾病和实验室检查异常。
  • 1例治疗相关死亡由肺炎导致,可能与同期使用胺碘酮有关。

关键数值与推荐

  • 12周疾病控制率为47%,部分缓解率24%。
  • 任何级别治疗相关不良事件76%,3-4级26%。
  • PD-L1肿瘤细胞表达率27%,与疗效无相关性。

临床怎么用

  • 对于经治复发性恶性胸膜间皮瘤,可考虑单药纳武利尤单抗治疗。
  • 治疗期间需监测肺炎等免疫相关不良事件,尤其注意合并用药相互作用。
  • 目前不宜依据PD-L1表达筛选纳武利尤单抗治疗人群。

局限性

  • 单中心、小样本探索性试验(34例)。
  • 未设对照组,疗效结果需更大样本随机研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Malignant pleural mesothelioma (MPM) has limited treatment options and a poor outcome. Programmed death 1/programmed death ligand 1 (PD-L1) checkpoint inhibitors have proven efficacious in several cancer types. Nivolumab is a fully humanized monoclonal antibody against programmed death 1 with a favorable toxicity profile. In MPM, the immune system is considered to play an important role. We therefore tested nivolumab in recurrent MPM. METHODS: In this single-center trial, patients with MPM received nivolumab 3 mg/kg intravenously every 2 weeks. Primary endpoint was the disease control rate at 12 weeks. Pre- and on-treatment biopsy specimens were obtained to analyze biomarkers for response. RESULTS: Of the 34 patients included, 8 patients (24%) had a partial response at 12 weeks and another 8 had stable disease resulting in a disease control rate at 12 weeks of 47%. One reached a partial response at 18 weeks. In 4 patients with stable disease, the tumor remained stable for more than 6 months. Treatment-related adverse events of any grade occurred in 26 patients (76%), most commonly fatigue (29%) and pruritus (15%). Grades 3 and 4 treatment-related adverse events were reported in 9 patients (26%), with pneumonitis, gastrointestinal disorders, and laboratory disorders mostly seen. One treatment-related death was due to pneumonitis and probably initiated by concurrent amiodarone therapy. PD-L1 was expressed on tumor cells in nine samples (27%), but did not correlate with outcome. CONCLUSIONS: Single-agent nivolumab has meaningful clinical efficacy and a manageable safety profile in pre-treated patients with mesothelioma. PD-L1 expression does not predict for response in this population.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Quispel-Janssen J, van der Noort V, de Vries JF, et al. Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma. J Thorac Oncol. 2018. PMID: 29908324. doi:10.1016/j.jtho.2018.05.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。